SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverNOVN.SW
HealthcareSIXEUR

Novartis AG

€001234567890012345678900123456789.0012345678900123456789+3.0%
52w low (est.) €100.49€153.43 52w high (est.)
Peers
Market data
Market cap
CHF237.14B
52-week range
CHF91.20 – CHF131.00
Beta (vs market)
0.49
Sector
Healthcare
Valuation
P/E ratio
22.0x
DCF fair value
CHF49.71
Margin of safety
-59.7%
Forward P/E
15.8x
PEG ratio
4.20
Dividend yield
2.98%
Quality & efficiency
Moat score
82/100
Return on equity
34.9%
Profit margin
23.9%
Debt / equity
1.21
Growth & analysts
Revenue growth (YoY)
-0.7%
Analyst target
CHF124.13
Target upside
+0.7%
Analysts covering
21

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Valuation

ValueGrowthProfitHealthIncome43QUALITY
Overall Rating
52
Hold
Hold
Moat Score82
DCF Intrinsic Value
CHF49.71-59.7% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
CHF237.14B
P/E Ratio
22.0
Dividend Yield
2.98%
Revenue Growth
-0.7%
Profit Margin
23.9%
ROE
34.9%
Debt / Equity
1.21
Beta
0.49
Dividend Aristocrats
vs Healthcare sector:P/E 22 vs 28 · cheaperMoat 82 vs 7Yield 2.98% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · NOVN.SW